NNNS: Stevia (stevioside) (2010)
Only non-nutritive sweeteners approved by the FDA and considered to be safe for human consumption are included in the N&NNS evidence analysis project. These include: acesulfame-K, aspartame, neotame, saccharin, stevia, and sucrolose. For more information, click Adverse Effects in the lower left.
In adults, is there evidence regarding the influence of stevia on metabolic outcomes and/or weight?
Five randomized controlled trials (Barriocanal et al 2008, Maki et al, 2008, Ferri et al, 2006, Gregerson et al, 2004, Hsieh et al, 2003) examined the effects of stevia compared to placebo on metabolic outcomes or weight and reported minimal, if any effects, on blood glucose and insulin levels, hypertension and weight. However, the majority of the trials were of small sample size and used varying doses of stevia.
One trial (Barriocanal 2008) in subjects with type 1 or type 2 diabetes or without diabetes reported no significant (NS) changes from baseline in serum glucose or HbA1C levels. However, one trial (Gregerson 2004) in subjects with type 2 diabetes reported a reduced postprandial blood glucose and glucagon response after a test meal of stevia vs. placebo. In subjects without diabetes, one trial (Ferri 2006) reported both glucose and insulin reductions in both the stevia and placebo groups.
Two trials (Barriocanal 2008, Maki 2008) in subjects with normal/low blood pressure (BP) detected NS changes from baseline in BP from stevioside compared to controls. In subjects with Stage 1 hypertension (HTN) no anti-hypertensive effects of stevioside compared to placebo were found (Ferri 2006). A third study (Gregerson 2004) also reported no changes in BP from stevioside compared to placebo. However, a two-year trial in Chinese subjects with mild HTN reported decreases in BP from stevia compared to placebo (Hsieh 2002).
Only one trial studied weight change and reported no change (Hsieh 2003).
- Grade I means there is Good/Strong evidence supporting the statement;
- Grade II is Fair;
- Grade III is Limited/Weak;
- Grade IV is Expert Opinion Only;
- Grade V is Not Assignable.
Evidence Summary: In adults, is there evidence regarding the influence of stevia on metabolic outcomes and/or weight?
- Quality Rating Summary
For a summary of the Quality Rating results, click here.
- Barriocanal LA, Palacios M, Benitez G, Benitez S, Jimenez JT, Jimenez N, Rojas V. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in Type 1 and Type 2 diabetics. Regul Toxicol Pharmacol. 2008; 51 (1): 37-41.
- Ferri LA, Alves-Do-Prado W, Yamada SS, Gazola S, Batista MR, Bazotte RB. Investigation of the antihypertensive effect of oral crude stevioside in patients with mild essential hypertension. Phytother Res. 2006; 20(9): 732-736.
- Antihyperglycemic effects of stevioside in type 2 diabetic subjects. Gregersen S, Jeppesen PB, Holst JJ, Hermansen K. Metabolism. 2004 Jan; 53 (1): 73-76. PMID: 14681845 [PubMed; indexed for MEDLINE]
- Hsieh MH, Chan P, Sue YM, Liu JC, Liang TH, Huang TY, Tomlinson B, Chow MS, Kao PF, Chen YJ. Efficacy and tolerability of oral stevioside in patients with mild essential hypertension: A two-year, randomized, placebo-controlled study. Clin Ther. 2003 Nov; 25(11): 2,797-2,808. PMID: 14693305.
- Maki KC, Curry LL, Carakostas MC, Tarka SM, Reeves MS, Farmer MV, McKenney JM, Toth PD, Schwartz SL, Lubin BC, Dicklin MR, Boileau AC, Bisognano JD. The hemodynamic effects of rebaudioside A in healthy adults with normal and low-normal blood pressure. Food Chem Toxicol. 2008; 46 Suppl. 7: S40-S46.
Search Plan and Results: Stevia - 2009